ClinicalTrials.gg
Status unknownNCT04133259Updated Oct 20, 2020

Evaluate the Efficacy and Safety of HLX10 in Chronic Hepatitis B Patients

A Phase 2 interventional study of Recombinant anti-programmed death-1 (PD-1) humanized monoclonal antibody and Nucleoside/nucleotide analogues in Hepatitis B, Chronic, sponsored by Henlix, Inc. Status unknown at 3 sites in Taiwan. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2020-10-20.

Sponsored by Henlix, Inc · Phase 2, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Oct 2020), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
44
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 99 studies in Hepatitis B, Chronic with a site in Taiwan — 3 open to participants now, 10 under way, 1 of them phase 3. Hepatitis B, Chronic · Taiwan.

Planned enrollment
69th of 88
44 · median 120
Started
2019
with 3 others
Phase 2
26 of 99
1 open now
Registered
65th of 99
by date

Among the 99 studies in Hepatitis B, Chronic with a site in Taiwan, this one is the 69th largest by planned enrollment of the 88 interventional ones that give a count, is one of 4 that started in 2019, is one of 26 in phase 2, and was the 65th registered.

Hepatitis B, Chronic

896 studies on the registry are indexed under Hepatitis B, Chronic; 153 are open to participants now.

Browse Hepatitis B, Chronic studies →

Open to participants now

3 of the 99 studies in Hepatitis B, Chronic with a site in Taiwan are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Taiwan have not opened yet or have stopped. Only those recruiting at a site in Taiwan →

Who these studies take

Of the 97 Hepatitis B, Chronic studies recruiting now, 33 (34%) set no upper age limit and 59 (61%) stop at 75 or younger; 11 take children under 18; 13 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 99 studies in Hepatitis B, Chronic with a site in Taiwan, or all of them as a file.
02

Study summary

A multiple-center, open-label, Phase II clinical trial to evaluate the safety and the efficacy of HLX10 in chronic hepatitis B patients.

Read the detailed description

This study is multiple-center, open-label, Phase II clinical trial and uses Simon's Two-Stage Optimal design. Subjects with chronic hepatitis B (CHB) will be enrolled sequentially and receive up to 3 doses of HLX10 at 1 mg/kg for four weeks apart.

First six subjects will be enrolled in the safety run-in period. If there are no serious adverse events noticed in these 6 subjects up to 6 weeks after the last infusion of HLX10, additional 11 subjects will be enrolled. These 17 subjects (6+11) will be evaluated for efficacy. In the second stage of trial, 27 additional subjects will be enrolled. Total 44 subjects [stage I (n=17) + stage II (n= 27) = total (n=44)] will be accrued in this study.

03

Conditions studied

  • Hepatitis B, Chronic

Browse trials for

Keywords

  • Hepatitis B, Chronic
  • Monoclonal antibody
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Eligible subjects must be 18 years of age or older or per local regulations and younger than 65 years.
  2. Subjects with chronic infection with serum HBsAg level > 100 IU/mL. [Chronic hepatitis B infection/carrier status must be confirmed by at least two laboratory results of persistent hepatitis B virus (HBV) infection (positive HBs antigen or HBV DNA) collected 6 months apart before the first infusion of HLX10.]
  3. Achieved viral suppression, defined as: HBV DNA level (checked within 4 weeks before the first dose of HLX10) lower than 2000 IU/mL.
  4. Subjects must be either (1) under nucleoside/nucleotide analogues (NAs) therapy and has achieved viral suppression at the time of study entry or (2) who currently are not taking anti-viral NAs but be able and willing to take one of the designated NAs for a duration of 14 to 22 weeks (2 weeks before the first dose of HLX10, up to 8 weeks during treatment, 12 weeks after the last dose of HLX10).
  5. HBe antigen (checked within 4 weeks before the first dose of HLX10) must be negative.
  6. (ECOG) performance status of ≤ 1 at the time of study entry.
  7. Able to provide .
  8. Adequate hematologic functions, as defined by: a normal white blood cell count, a normal ; a level ≥ 10 gm/dL and a count ≥ 100,000/mm3.
  9. Adequate hepatic function defined by: a normal total level, (ALT) level and a of INR \< 1.5 times normal.
  10. Adequate renal function, as defined by the rate ≥ 50 mL/minute calculated using Cockcroft-Gault formula. In subject with extreme body weight ( \< 18.5 or > 30), estimated (eGFR) > 50 mL/min calculated using Modification of Diet in Renal Disease (MDRD) formula is acceptable.
  11. Adequate cardiac function defined as (LVEF) ≥ 50% measured by multigated acquisition (MUGA) scan or cardiac ultrasound.
  12. Use of effective measures if procreative potential exists .
  13. Able to be followed up the procedures as required by the study protocol.

Exclusion criteria

Exclusion Criteria:

  1. Concurrent unstable or uncontrolled medical conditions which include either one of the followings:

    • Active systemic infections that necessitate antimicrobial therapy;
    • Poorly controlled hypertension (systolic blood pressure ≥ 160 mmHg or diastolic blood pressure ≥100 mmHg), or poor compliance with anti-hypertensive agents;
    • Acute myocardial infarction within 12 months OR arrhythmia, unstable angina pectoris, congestive heart failure (class III or IV of [NYHA]);
    • Uncontrolled diabetes ( > 9.5% in past three months) or poor compliance with hypoglycemic agents;
    • The presence of chronically unhealed wound or ulcers;
    • Other chronic diseases, which, in the opinion of the investigator, could compromise safety of the subject or the integrity of study.
  2. Any concurrent other than basal cell carcinoma or carcinoma in situ of the cervix. (Subjects with a previous malignancy without history of liver involvement and without evidence of disease for ≥ 3 years can participate).
  3. Pregnancy (confirmed by urine beta human chorionic gonadotropin [ßHCG]) or breast-feeding.
  4. History of infection (HIV). All subjects must agree to undergone screening for HIV.
  5. Subject who has an active or a documented history of disease (must be confirmed by negative antinuclear antibodies (ANA), rheumatic factor (RF) and anti-double stranded DNA level (anti-dsDNA)).
  6. Subject who currently has (defined as anti-HCV antibody reactive or detectable HCV RNA > 15 IU/L) or hepatitis D (defined as anti-HDV antibody reactive).
  7. Subject who has a history of interstitial lung disease.
  8. Have a condition requiring systemic treatment with either (> 10 mg daily prednisone equivalents) or other medications within 14 days of study drug administration. Inhaled or topical steroids and adrenal replacement doses > 10 mg daily prednisone equivalents are permitted in the absence of autoimmune disease.
  9. The subject is the investigator, sub-investigator or any one directly involved in the conduct of the study.
  10. Subject has a history or current evidence of any condition or disease that could confound the results of the study or is not the best interest of the subject to participate, in the opinion of Investigator.
  11. History of alcoholism OR recreational drug use.
  12. Preexisting advanced liver disease and cirrhosis subject: advanced hepatic fibrosis and cirrhosis are defined as Fibroscan ≥ 9.5 Kpa or Acoustic radiation force impulse (ARFI) ≥ 1.81 m/sec or Fibrosis-4 (FIB-4) ≥ 3.25 or METAVIR F ≥ 3.
Terms in these criteria, in plain language(23)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
44 participants (estimated)

Study arms

  • Experimental
    HLX10, in patients with CHB

    HLX10: 1 mg/kg at 0, 4th, 8th week (maximum 3 doses). Concomitant antiviral medications: take Nucleoside/nucleotide analogues (NAs) starting from at least 2 weeks before the first dose of HLX10 until 12 weeks after the last dose of HLX10 infusion.

    Drug: Recombinant anti-programmed death-1 (PD-1) humanized monoclonal antibody · Drug: Nucleoside/nucleotide analogues

Interventions

06

What researchers measure

Primary outcomes

  1. The proportion of the subjects who achieve 0.5 log decline in HBsAg log10 IU/mL from baseline

    Efficacy of HLX10 for treatment of chronic HBV

    Time frame: 12 week

Secondary outcomes

  1. The proportion of the subjects who achieve 1 log decline in HBsAg log10 IU/mL from baseline

    Efficacy of HLX10 for treatment of chronic HBV

    Time frame: 24 weeks

  2. The proportion of subjects with chronic hepatitis B that achieve HBsAg seroclearance after receiving treatment with HLX10.

    HLX10 for curative treatment of chronic HBV

    Time frame: 9 months

  3. The proportion of subjects with chronic hepatitis B who suffered from hepatitis flare after receiving HLX10

    Safety of HLX10 in treatment of chronic HBV

    Time frame: 9 months

07

Study locations

3 of 3 sites recruiting
  • Kaohsiung Medical University Chung-Ho Memorial Hospital
    Kaohsiung, Taiwan
    Recruiting
    • Chia-Yen Dai, MD, PhD · Contact
  • China Medical University Hospital
    Taichung, Taiwan
    Recruiting
    • Cheng-Yuan Peng, MD, PhD · Contact
  • National Taiwan University Hospita
    Taipei, Taiwan
    Recruiting
    • Jia-Horng Kao, MD, PhD · Contact
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2019 (actual). Primary completion is estimated for Apr 2022, 27 months after the start.

Of 75 industry-sponsored phase 2 interventional studies under Hepatitis B, Chronic, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 39. This study's planned 27 months is above that.

Counting every sponsor, half of 87 studies reached it within 23 months; a quarter within 16 and three quarters within 41.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 1, 2019
First posted
Oct 21, 2019
StartActual
Dec 31, 2019
Primary completionEst.
Apr 30, 2022
CompletionEst.
Jul 30, 2022
Last update
Oct 20, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 20, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04133259
Lead sponsor
Henlix, Inc
Responsible party
Sponsor
First posted
Oct 21, 2019
Start date
Dec 31, 2019
Primary completion
Apr 30, 2022 (estimated)
Completion
Jul 30, 2022 (estimated)
Last update
Oct 20, 2020

Study contacts

Jia-Ling Lee
Contact
jlee@henlix.com
+886-2-792-7927 ext. 105
Jia-Horng Kao, MD, PhD
principal investigator · National Taiwan University Hospital
Cheng-Yuan Peng, MD, PhD
principal investigator · China Medical University Hospital
Chia-Yen Dai, MD, PhD
principal investigator · Kaohsiung Medical University Chung-Ho Memorial Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Oct 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Programmed Cell Death 1 Receptor

Start the discussion